Article
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
British journal of haematology - 1 Sept 2024
Kugler Eitan, Cohen Inbar, Amitai Irina, Ram Ron, Frisch Avraham, Nachmias Boaz, Canaani Jonathan, Moshe Yakir, Krayem Baher, Aumann Shlomzion, Henig Israel, Vainstein Vladimir, Shargian Liat, Ganzel Chezi, Yeshurun Moshe, Levi Itay, Raanani Pia, Akria Luiza, Ofran Yishai, Shimony Shai, Wolach Ofir
Abstract excerpt
Patients with FLT3-mutated acute myeloid leukaemia (AML) that relapse or are refractory (R/R) to intensive induction have poor outcomes. Gilteritinib has recently become standard-of-care for patients with R/R FLT3-mutated AML. We investigated whether adding venetoclax to gilteritinib (gilt-ven) improves outcomes as compared with gilteritinib monotherapy. We included patients treated with gilteritinib (n = 19) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.